No Data
Is United Therapeutics Corporation's (NASDAQ:UTHR) Recent Stock Performance Tethered To Its Strong Fundamentals?
United Therapeutics Publishes Its 2024 Corporate Responsibility and Public Benefit Report Highlighting Its Progress Toward a Future Where No Patient Gets Left Behind—Ever
United Therapeutics Insider Sold Shares Worth $2,821,050, According to a Recent SEC Filing
US stocks dig gold | New milestone! Berkshire Hathaway's market cap breaks through the trillion-dollar mark! Analysts continue to be bullish; excellent performance stocks are ecstatic! Chewy, a pet retail stock, soared over 11%.
Lockheed Martin received a $5 billion large order, with the stock price breaking through the year-high; the warming expectation of interest rate cuts is bullish for bank stocks, with JPMorgan's PE ratio at 12 times, the stock price is undervalued.
Liquidia Seeks Stay on FDA Exclusivity Approval of Rival Version of Hypertension Drug
Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday